Connect with us

Health

BC counts 605 new cases of COVID-19 Wednesday, 4 deaths – Hope Standard – Hope Standard

Published

 on


B.C. public health teams reported another 605 confirmed COVID-19 cases on Wednesday, with more than a third of them in the Fraser Health region.

There were four additional coronavirus-related deaths recorded Oct. 13, three of them in the Northern Health region where hospitals have been at capacity with seriously ill people and have been transferring intensive care patients to facilities in the Lower Mainland and on Vancouver Island.

Province-wide, there are 374 people in hospital with active COVID-19 infections, up by 17 from Tuesday, with 153 of them in intensive care, the same as Tuesday.

One new infection outbreak has been declared, at Tofino General Hospital, and an outbreak at the Residence in Mission senior care facility has been declared over. That leaves 19 active outbreaks, including areas at Mission Memorial Hospital, University Hospital of Northern B.C. and 16 long-term care or assisted living homes in the province.

From Oct. 5-11, people not fully vaccinated accounted for 68.0% of cases and from Sept. 28-Oct. 11, they accounted for 73.4% of hospitalizations.

B.C. health authorities continue to operate scheduled appointment and walk-in COVID-19 vaccination clinics around the province. A full list of clinic locations and hours by region can be found here. Registration and booking appointments in B.C. can be done here, or by calling 1-833-838-2323 between 7 a.m. and 7 p.m. seven days a week.

RELATED: B.C. senior care staff now 96% vaccinated for COVID-19

RELATED: Trick-or-treat in small groups, Dr. Henry advises

New and active cases for Oct. 13 by region:

• 245 new cases in Fraser Health, 2,214 active

• 82 new cases in Vancouver Coastal Health, 721 active

• 119 new cases in Interior Health, 850 active

* Total active cases: 850

• 67 new cases in Northern Health, 689 active

• 92 new cases in Island Health, 640 active


@tomfletcherbc
tfletcher@blackpress.ca

Like us on Facebook and follow us on Twitter.

BC legislatureCoronavirus

Adblock test (Why?)



Source link

Continue Reading

Health

Facebook, YouTube take down Bolsonaro video over false vaccine claim

Published

 on

Facebook and YouTube have removed from their platforms a video by Brazilian President Jair Bolsonaro in which the far-right leader made a false claim that COVID-19 vaccines were linked with developing AIDS.

Both Facebook and Alphabet Inc’s YouTube said the video, which was recorded on Thursday, violated their policies.

“Our policies don’t allow claims that COVID-19 vaccines kill or seriously harm people,” a Facebook spokesperson said in a statement on Monday.

YouTube confirmed that it had taken the same step later in the day.

“We removed a video from Jair Bolsonaro’s channel for violating our medical disinformation policy regarding COVID-19 for alleging that vaccines don’t reduce the risk of contracting the disease and that they cause other infectious diseases,” YouTube said in a statement.

According to the Joint United Nations Programme on HIV and AIDS (UNAIDS), COVID-19 vaccines approved by health regulators are safe for most people, including those living with HIV, the virus that causes acquired immunodeficiency syndrome, known as AIDS.

Bolsonaro’s office did not respond immediately to a request for comment outside normal hours.

In July, YouTube removed videos from Bolsonaro’s official channel in which he recommended using hydroxychloroquine and ivermectin against COVID-19, despite scientific proof that these drugs are not effective in treating the disease.

Since then, Bolsonaro has avoided naming both drugs on his live broadcasts, saying the videos could be removed and advocating “early treatment” in general for COVID-19.

Bolsonaro, who tested positive for the coronavirus in July last year, had credited his taking hydroxychloroquine, an anti-malarial drug, for his mild symptoms. While Bolsonaro himself last January said that he wouldn’t take any COVID-19 vaccine, he did vow to quickly inoculate all Brazilians.

In addition to removing the video, YouTube has suspended Bolsonaro for seven days, national newspapers O Estado de S. Paulo and O Globo reported, citing a source familiar with the matter.

YouTube did not respond to a separate Reuters request for comment regarding the suspension on Monday night.

(Reporting by Pedro Fonseca in Rio de Janeiro; Additional reporting by Gram Slattery in Rio de Janeiro and Anthony Boadle in Brasilia; Writing by Gabriel Araujo; Editing by Leslie Adler)

Continue Reading

Health

Exclusive: African Union to buy up to 110 million Moderna COVID-19 vaccines – officials

Published

 on

The African Union (AU) intends to buy up to 110 million doses of COVID-19 vaccine from Moderna Inc in an arrangement brokered in part by the White House, which will defer delivery of some doses intended for the United States to facilitate the deal, officials told Reuters.

The AU’s doses will be delivered over the coming months, with 15 million arriving before the end of 2021, 35 million in the first quarter of next year and up to 60 million in the second quarter.

“This is important as it allows us to increase the number of vaccines available immediately,” AU coronavirus envoy Strive Masiyiwa said in an email. “We urge other vaccine producing countries to follow the lead of the (U.S. government) and give us similar access to buy this and other vaccines.”

Masiyiwa said the Moderna purchase represented the first time the 55-member AU had secured vaccines that were not fully produced in Africa.

The new shipments of vaccine are well below what Africa needs to vaccinate its 1.3 billion people, who have had far less access to the life-saving vaccines than more prosperous parts of the world. Getting access to Moderna vaccines adds diversity to the AU’s vaccine supply with different storage requirements.

The Biden administration is deferring delivery of 33 million doses it had bought from Moderna to give the AU its “spot in line” to make a purchase, according to Natalie Quillian, the White House’s deputy coordinator for COVID-19 response.

“We are grateful to have helped negotiate this encouraging step forward between Moderna and the African Union that will significantly expand access to vaccines on the continent in the near-term,” Quillian said.

The United States, which has seen more than 700,000 people die from COVID-19, is flush with vaccines. The delayed Moderna deliveries will not have an impact on efforts to provide booster shots to already inoculated Americans, Quillian said.

Moderna said it was working to make it possible to fill doses of its COVID-19 vaccine in Africa by 2023 and has plans to build a manufacturing plant on the continent.

“This is the first step in our long-term partnership with the African Union,” Moderna Chief Executive Stéphane Bancel said in a statement, referring to a Memorandum of Understanding to make up to 110 million doses for the AU.

Last month, the AU accused https://www.reuters.com/article/health-coronavirus-who/update-1-african-union-slams-vaccine-manufacturers-for-restricting-access-idINL8N2QG4CK COVID-19 vaccine manufacturers of denying African countries a fair chance to buy vaccines and urged manufacturing countries, in particular India, to lift export restrictions on vaccines and their components.

 

(Reporting by Jeff Mason; Editing by Robert Birsel)

Continue Reading

Business

Analysis: Capitol Hill drug pricing reform opponents among the biggest beneficiaries of pharma funds

Published

 on

Democratic Party lawmakers holding up proposed drug pricing reforms are among the largest beneficiaries of the pharmaceutical industry’s push to stave off price cuts, a Reuters analysis of public lobbying and campaign data shows.

The industry, which traditionally gives more to Republicans, channeled around 60% of donated campaign funds to Democrats this year. It has spent over $177 million on lobbying and campaign donations in 2021.

Nonprofit political action committees (PACs) run by Pfizer Inc and Amgen Inc and the Pharmaceutical Research and Manufacturers of America (PhRMA) were among the biggest donors, according to political spending data from OpenSecrets, formerly the Center for Responsive Politics.

Drugmakers are seeking to block laws that would give the U.S. government authority to negotiate prices for prescription medicines. Current U.S. law bars the government’s Medicare health insurance program from negotiating drug prices directly.

Many of the Democrats opposing an ambitious drug reduction bill proposed in the House of Representatives are among some of the biggest recipients of drug manufacturer lobbying funds.

They include Senators Kyrsten Sinema of Arizona, Robert Menendez of New Jersey, and Representative Scott Peters of California, OpenSecrets data covering industry donations through September of 2021 shows. In all, they have received around $1 million in pharmaceutical and health product industry donations this year.

A spokesperson for Sinema did not respond to a request for comment on the funds she has received but said the Senator supports making drugs as cheap as possible for patients.

Menendez and Peters said the donations did not influence their views. All three said they are opposed to The Lower Drug Costs Now Act, which is sponsored by Democrats in the House of Representatives and also known as H.R.3.

Menendez and Peters have advocated for alternative scaled-back drug pricing reforms that would still allow Medicare to negotiate drug prices but would lead to significantly smaller savings.

Congressman Frank Pallone of New Jersey, who is also one of the top recipients of drugmaker donations, voted in favor of H.R.3.

Sinema, who campaigned in 2018 on cutting drug prices, told the White House she opposes allowing Medicare to negotiate them. She received about $466,000 from the industry in 2021, according to OpenSecrets data.

Peters was the top recipient of pharmaceutical industry funds in the House this year at nearly $99,550, according to OpenSecrets data. A spokesperson said Peters was not influenced by lobbying money and opposed the proposed law to protect pharmaceutical industry jobs and innovation.

Drugmakers say the Democrats’ proposed drug price overhaul would undermine their ability to develop new medicines, an argument they have used whenever price cuts are discussed by politicians regardless of political party.

“Patients face a future with less hope under Congress’ current drug pricing plan,” PhRMA Chief Executive Steve Ubl said in an August statement in reference to the proposed law. PhRMA declined to comment on donating to key Democratic opponents of the bill.

The United States is an outlier as most other developed nations do negotiate drug prices with manufacturers.

Amgen did not immediately respond to requests for comment on its donations and Pfizer declined to comment.

PROSPECTS FOR REFORM

President Joe Biden has vowed to cut medicine costs, in part by allowing the federal government to negotiate drug payments by Medicare, which covers Americans aged 65 and older.

But prospects for major drug pricing reforms have stalled in recent weeks amid opposition from centrist Democrats including Sinema and Peters. Negotiations are ongoing, eight Democratic staffers said.

The lawmakers’ resistance comes as 83% of Americans support allowing Medicare to negotiate medicine costs, according to a Kaiser Family Foundation poll. The United States spends more than twice as much per person on drugs as other wealthy economies, about $1,500, for a total of around $350 billion in 2019.

“Members of Congress don’t always mirror the views of the public and the pharmaceutical industry is a powerful lobbying force,” said Larry Levitt, a health economist at Kaiser.

The healthcare industry is the second largest industry lobbying group in the United States behind the finance sector. It donated more than $600 million to politicians ahead of the 2020 elections.

The pharmaceutical industry has spent hundreds of millions of dollars per year to sway federal and state policy. But current Democratic leadership has the industry concerned major reforms could actually be enacted and is working harder to offer alternatives such as reducing insurance co-pays, one industry source said. “It’s been sort of a mad scramble.”

Corporations in the United States are not permitted to make direct contributions to candidates but can give money through PACs. Most corporate PACs, including Pfizer’s and Amgen’s, are run by company managers and employees.

Democrats and some drug price experts say the Lower Drug Costs Now Act could save U.S. taxpayers and consumers billions annually with relatively minor impact on innovation.

A House Oversight and Reform Committee report showed that top drugmakers have spent around $50 billion more on share buybacks and dividends than research and development between 2016 and 2020.

Lovisa Gustafsson, a healthcare policy analyst at the Commonwealth Fund, a non-profit healthcare advocacy group, said, “There are other ways that we can incentivize innovation, aside from just paying huge margins for pharmaceutical companies.”

 

(Reporting by Ahmed Aboulenein in Washington and Carl O’Donnell in New York; Editing by Caroline Humer and Bill Berkrot)

Continue Reading

Trending